NCT02392455已完成不适用
Vargatef in 2nd-line Therapy of Advanced or Metastatic Adenocarcinoma of the Lung
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 817
- 主要终点
- Percentage of patients alive one year after start of therapy with Vargatef and Docetaxel (1-year survival rate)
研究概览
简要总结
This observational study will investigate the efficacy and tolerability of Vargatef (Nintedanib) plus docetaxel in daily routine second-line treatment in patients with locally advanced, metastatic or locally recurrent NSCLC. Treatment with Vargatef in eligible NSCLC patients, for whom the treating physician has decided to initiate treatment with Vargatef in second line according to the local label, will be observed for up to 24 months. Survial follow-up will be done until the end of the study.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
A
干预措施: treatment (Drug)
结局指标
主要结局
Percentage of patients alive one year after start of therapy with Vargatef and Docetaxel (1-year survival rate)
时间窗: up to 24 months
次要结局
- Tumour control rate (complete response, partial response, stable disease)(up to 24 months)
- Incidence of side effects(up to 24 months)
- One year survival rate of patients with first line progression within 9 months after start of first line therapy(up to 24 months)
- Progression-free survival of patients with first line progression within 9 months after start of first line therapy(up to 24 months)
- Median overall survival(up to 24 months)
- Progression-free survival(up to 24 months)
研究者
相似试验
已完成
2 期
VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the UrotheliumAdenocarcinoma of the BladderDistal Urethral CancerMetastatic Transitional Cell Cancer of the Renal Pelvis and UreterProximal Urethral CancerRecurrent Bladder CancerRecurrent Transitional Cell Cancer of the Renal Pelvis and UreterRecurrent Urethral CancerSquamous Cell Carcinoma of the BladderStage III Bladder CancerStage III Urethral CancerStage IV Bladder CancerTransitional Cell Carcinoma of the BladderUrethral Cancer Associated With Invasive Bladder CancerNCT00407485National Cancer Institute (NCI)22
已完成
2 期
Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or GliosarcomaGliosarcomaGlioblastomaNCT00525525University of California, San Francisco74
已完成
2 期
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial CancerRecurrent Endometrial CarcinomaNCT00462826National Cancer Institute (NCI)49
已完成
2 期
VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by SurgeryCiliary Body and Choroid Melanoma, Medium/Large SizeExtraocular Extension MelanomaMetastatic Intraocular MelanomaRecurrent Intraocular MelanomaRecurrent MelanomaStage III MelanomaStage IV MelanomaIris MelanomaNCT00450255National Cancer Institute (NCI)41
已完成
2 期
Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue SarcomaFallopian Tube CancerFemale Reproductive CancerOvarian CarcinosarcomaOvarian SarcomaRecurrent Ovarian Epithelial CancerRecurrent Uterine SarcomaStage III Ovarian Epithelial CancerStage III Uterine SarcomaStage IV Ovarian Epithelial CancerStage IV Uterine SarcomaUterine CarcinosarcomaUterine LeiomyosarcomaNCT00390234National Cancer Institute (NCI)63